Last Updated: 28 May 2025
Source: Statifacts
The global radiopharmaceuticals market size surpassed USD 6,740 million in 2024 and is predicted to reach around USD 14,440 million by 2034, registering a CAGR of 8.2% from 2025 to 2034.
| Industry Worth | Details |
| Market Size in 2025 | USD 7,510 Million |
| Market Size by 2034 | USD 14,440 Million |
| Market Growth Rate from 2025 to 2034 | CAGR of 8.2% |
Radiopharmaceuticals are distinctive medicinal preparations containing radioactive isotopes used for diagnosis or treatment in nuclear medicine. The presence of growth steadily occurs because of the advancement in healthcare technologies and the increasing incidence of chronic diseases, while there has been an increase in the population of elderly people. Radiopharmaceuticals enable personalized medicine in terms of detailed diagnostic information and treatment approaches designed to further patient benefit. Newer radiopharmaceutical agents, having better diagnostic and therapeutic attributes, are borne out of research and development. There exist some concerns that limit the workings of the industry, such as extreme regulatory issues, a high cost of manufacturing, safety issues regarding handling radioactive materials, the disposal of such materials, etc. Furthermore, the high capital-intensive nature of the manufacturing plant tends to obstruct the arrival of smaller players. Regardless of the above challenges, there exist enormous opportunities for companies willing to invest in next-generation diagnostics and therapeutics. Moving forward, strategic collaborations between pharmaceutical companies, healthcare providers, and academic institutions will considerably accelerate the pace of innovations as healthcare systems worldwide target early detection and precision treatment.
“We are pleased to integrate this cutting-edge technology into our portfolio for our clients. The AbYlink™ technology gives the advantage of generating reproducible batches of bioconjugated antibodies and ADCs that secure the specificity and efficacy of targeted radiotherapy.”
"We are delighted to be working with Radiomer Therapeutics in radiopharmaceutical development."
North America
North America leads the world market in radiopharmaceuticals, exhibiting ceaseless growth through its unyielding advancement of healthcare infrastructure; therein lie strong research and developmental capacities, plus a craving for superior diagnostic and therapeutic solutions. With things more or less sharply controlled by the thin regulatory framework, the reimbursement policies settled down firmly on the laboratory table, and radiopharmaceutical companies, both pharmaceutical and radiopharmaceutical, being dense in numbers, the region stands as an enriched sphere for radiopharmaceutical production and usage.
Asia-Pacific
Asia-Pacific is expected to grow at the fastest rate during the forecast period. Further enhancing the command on the market is the adoption of the latest imaging technologies and an unfaltering pursuit of innovation in medicine. The increasing existence of chronic diseases and an advancing ageing population are making the Asia-Pacific region grow fast. Expansion of healthcare infrastructure, availability of modern medical technologies, and increasing awareness about the advantages of nuclear medicine are supporting the market growth.
Europe
Europe also holds a big share of the global market, supported by a sound healthcare system, intensive research and clinical innovations, and supportive policies in the background. Consequently, these factors render Europe a major looker on in the global radiopharmaceuticals landscape.
The market is moderately fragmented with local players like Bayer AG, Iso-Tex Diagnostics, Inc, Jubilant Pharmova Limited, Novartis AG, General Electric Company, Lantheus Holdings, Inc., Eli Lilly and Company, Siemens AG, Curium Pharma, Cardinal Health Inc., wishing to take the time to edge their presence through investments, partnerships, acquisitions, and mergers. They also invest in product development and competitive pricing. These strategies will promote market growth and lucrative opportunities for market players
According to Jubilant Pharmova's latest financial reports, the company's current revenue (TTM) is ₹71.13 billion. An increase in revenue in the year 2023, that were of ₹65.59 billion.
According to Eli Lilly's latest financial reports, the company's current revenue (TTM) is ₹4.172 trillion. In 2024, the company made a revenue of ₹3.864 Trillion, an increase over the revenue in the year 2023, that were of ₹2.840 Trillion
According to Siemens's latest financial reports, the company's current revenue (TTM) is ₹7.092 trillion. An increase in revenue in the year 2023, that were of ₹6.854 Trillion.
Published by Ajit Bansod
